4. LivaNova (Nasdaq:LIVN): +77.7%Formed by the $2.7 billion merger of Italy’s Sorin and Cyberonics in October 2015, LivaNova (London) continues to expand its offerings in neuromodulation – which remains one of the hottest areas of growth in the medical device industry. The company in October announced FDA approvals for its latest vagus nerve stimulation therapy system – the SenTiva implantable generator and the next-generation VNS therapy programming system – for the treatment of people with drug-resistant epilepsy. Over the past week, LivaNova announced it would buy ImThera Medical and its implantable sleep apnea treatment for $225 million.
During its third quarter, the company swung to profitability and upped its earnings outlook for the rest of 2017.